Levetiracetam - Aprecia Pharmaceuticals

Drug Profile

Levetiracetam - Aprecia Pharmaceuticals

Alternative Names: CNS disorder therapeutic - Aprecia Pharmaceuticals; Product 1 - Aprecia Pharmaceuticals; Spritam

Latest Information Update: 24 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aprecia Pharmaceuticals
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Seizures

Most Recent Events

  • 10 Jan 2017 Biomarkers information updated
  • 22 Mar 2016 Launched for Seizures (In adolescents, In children, In adults) in USA (PO) - First global launch
  • 31 Jul 2015 Registered for Seizures (In children, In adolescents, in adults) in USA - First Global Approval (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top